STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

JNJ JOHNSON & JOHNSON StockScouter® Report

4

StockScouter® Score

JOHNSON & JOHNSON, a large cap growth company in the healthcare sector, is expected to perform in line with the market over the next six months with less than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The enterprise value-to-sales ratio is approximately in line with that of comparably-sized companies in the StockScouter universe. Neutral
  • The most recent quarterly earnings report was approximately equal to or higher than analysts’ consensus forecast, but is not suggestive of future returns. Neutral

 

Concerns

  • Earnings growth in the past year has decelerated rapidly compared to earnings growth in the past three years. Negative
  • One or more analysts has modestly decreased quarterly earnings estimates for JNJ. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that large cap stocks will be neutral, growth stocks will be neutral, and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 20% done.
Progress: 60% done.
Low
High

Core Model Grades

D
D
C
C

Previous Ratings

5
4
4